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Bifurcation treatment
(N= 362)
Zotarolimus-Eluting
Resolute stent
(N = 179)
Everolimus-Eluting
Xience V stent
(N = 183)
Difference
(95% CI) p value
Target vessel
failure
23 (12.8) 21 (11.5) 1.4 (-5.4 to 8.1) 0.69
Death
Any cause 9 (5.0) 4 (2.2) 2.8 (-1.0 to 6.7) 0.15
Cardiac cause 4 (2.2) 2 (1.1) 1.1 (-1.5 to 3.8) 0.40
Target vessel
related MI
Any 14 (7.8) 14 (7.7) 0.2 (-5.4 to 5.7) 0.95
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMConclusions: This study demonstrated DES showed the same early, late and very late
thrombosis rate as BMS. In long term follow up, whether DM or non-DM patients,
DES had similar 5-year re-infarction rate and cardiovascular death as BMS in Asian
patients after AMI.
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Background: Polytetraﬂuoroethylene (PTFE)-covered stents have improved the in-
hospital clinical outcomes of patients with coronary perforation. However, there are
a few reports regarding their long-term outcomes.
Methods:We analyzed data that was prospectively collected from 17277 patients who
underwent percutaneous coronary intervention in New Tokyo Hospital between
January 2004 and December 2012. Of the total, we identiﬁed 238 (1.38%) patients
with coronary perforation. We then evaluated their mid-term clinical outcomes. The
study endpoints were major adverse cardiac events (MACEs), deﬁned as cardiac
death, myocardial infarction (MI), and target lesion revascularization (TLR).
Furthermore, individual parameters, including all-cause death, cardiac death, MI, TLR
and stent thrombosis (ST) during the follow-up period, were evaluated.
Results: Among the 238 patients with coronary perforation, 42 (17.6%) were treated
with PTFE-covered stents. All patients were followed-up for over 6 months (median
follow-up period, 1015 days; interquartile range, 401–1739 days). Although the all-
cause death rate was relatively high, at 11.9% because of complications associated
with coronary perforation, the cardiac death rate was 2.6% at 1 year (Figure). TLR
occurred in 5 patients, and it occurred within 3 months in 3 of these patients. MI
occurred in 1 patient because of side branch occlusion following PTFE-covered stent
implantation. No deﬁnite or probable ST was found.PMI 13 (7.3) 12 (6.6) 0.7 (-4.6 to 6.0) 0.79
Clinically
indicated TVR
Any 7 (3.9) 8 (4.4) -0.5 (-4.6 to 3.7) 0.83
Patient-oriented
composite
end-point
31 (17.3) 31 (16.9) 0.4 (-7.4 to 8.2) 0.92
Deﬁnite ST
(0-720 days)
1 (0.6) 1 (0.5) 0.0 (-1.5 to 1.5) 0.99
Deﬁnite or
probable ST
(0-720 days)
2 (1.1) 1 (0.5) 0.6 (-1.3 to 2.4) 0.55
Very late deﬁnite
or probable
ST (361-720)
1 (0.6) 1 (0.6) 0.0 (-1.5 to 1.5) 0.99
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Background: The aim of this study was to investigate safety and efﬁcacy of second-
generation zotarolimus-eluting Resolute stents and everolimus-eluting Xience V stents
in bifurcation lesions.
Methods: In TWENTE – a prospective, randomized DES trial – PCI patients were
randomized for treatment with contemporary Resolute or Xience V stents. Clinical
endpoints were adjudicated by an external independent clinical events committee
(Cardialysis CRO, Rotterdam, The Netherlands). Target vessel failure (TVF; cardiac
death, target vessel-related myocardial infarction, and clinically-indicated target vessel
revascularization), the primary endpoint of the TWENTE trial, was assessed after 2
years.
Results: Among the 1,391 patients of the TWENTE trial, 362 (26%) patients were
treated for at least one bifurcation lesion. Of these patients, 179 and 183 were
randomized for treatment with Resolute and Xience V stents, respectively. At 2-year
follow-up, TVF (12.8% vs. 11.5%; p¼0.69) and a patient-oriented composite endpoint
(17.3% vs. 16.9%; p¼0.92) did not differ signiﬁcantly between stent arms. In addi-
tion, rates of deﬁnite and or probable stent thrombosis were low and similar for both
stent arms (0.6% vs. 0.5%; p¼0.99). Within 213 (15.3%) patients, who were treated
for bifurcation lesions with an additional treatment of the side-branch, there was also
no signiﬁcant difference in TVF between patients treated with Resolute (n¼98) and
Xience V (n¼115) (8.2% vs. 11.3%; p¼0.44).
Conclusions: Treatment of bifurcation lesions with Resolute and Xience V stents
resulted in favorable and similar outcomes after 2 years in the randomized TWENTE
trial.acts/POSTER/Bare Metal and Drug-Eluting Stent Studies B61
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